// App-Quantinova.ai

2224 : Analgesic Potential of NEO6860, a Modality Selective TRPV1 Antagonist, in Osteoarthritis Knee Pain:  Results of a Randomized, Controlled, Proof-of-Concept Trial

Researchers

Presenter

  • Pierre Arsenault

Principal Investigators

  • Nathaniel Katz

  • Philippe Walker

  • Dan Chiche

Medical Centers

  • Richard Leff

  • Diex Recherche Sherbrooke, Sherbrooke, QC, Canada

  • Richard L Leff LLC, Chadds Ford, PA

  • Analgesic Solutions, Natick, MA

  • NEOMED Institute, Montreal, QC, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • N/A

Biomarkers

  • Body mass index

Drug/Treatment

  • Naproxen Sodium

  • NEO6860

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved